Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 7, 2018, Pages 555-563

  Beddhu, Srinivasan ^a,b   Greene, Tom ^b   Boucher, Robert ^b   Cushman, William C ^c   Wei, Guo ^b   Stoddard, Gregory ^b   Ix, Joachim H ^d   Chonchol, Michel ^e   Kramer, Holly ^f,g   Cheung, Alfred K ^a,b   Kimmel, Paul L ^h   Whelton, Paul K ⁱ   Chertow, Glenn M ^j  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g Veterans Affairs Medical Center in Hines   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ TULANE UNIVERSITY   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; COMPLICATION; DIABETIC COMPLICATION; GLOMERULUS FILTRATION RATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 85045840348     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30099-8     Document Type: Article

References (26)

1. Mills, KT, Bundy, JD, Kelly, TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134 (2016), 441–450.
2. James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
3. Hsu, CY, McCulloch, CE, Darbinian, J, Go, AS, Iribarren, C, Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 165 (2005), 923–928.
4. Rapsomaniki, E, Timmis, A, George, J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 383 (2014), 1899–1911.
5. Lewington, S, Clarke, R, Qizilbash, N, Peto, R, Collins, R, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
6. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
7. Williamson, JD, Supiano, MA, Applegate, WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA 315 (2016), 2673–2682.
8. Beddhu, S, Rocco, MV, Toto, R, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med 167 (2017), 375–383.
9. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
10. Ismail-Beigi, F, Craven, TE, O'Connor, PJ, et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81 (2012), 586–594.
11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
12. Ambrosius, WT, Sink, KM, Foy, CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
13. National Heart, Lung and Blood Institute. Systolic Blood Pressure Intervention Trial (SPRINT): protocol version 4.0. https://www.sprinttrial.org/public/Protocol_Current.pdf, Nov 1, 2012. (Accessed 20 March 2018)
14. National Heart, Lung and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) protocol. https://biolincc.nhlbi.nih.gov/static/studies/accord/Protocol.pdf?link_time=2017-08-22_13:28:23.544891, Jan 5, 2009. (Accessed 20 March 2018)
15. Andersen, PK, Klein, JP, Rosthøj, S, Generalised linear models for correlated pseudo-observations, with applications to multi-state models. Biometrika 90 (2003), 15–27.
16. Parner, ET, Andersen, PK, Regression analysis of censored data using pseudo-observations. Stata J 10 (2010), 408–422.
17. Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
18. Tancredi, M, Rosengren, A, Svensson, A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 373 (2015), 1720–1732.
19. Afkarian, M, Sachs, MC, Kestenbaum, B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24 (2013), 302–308.
20. Perkovic, V, Rodgers, A, Redefining blood-pressure targets: SPRINT starts the marathon. N Engl J Med 373 (2015), 2175–2178.
21. Brouwer, TF, Vehmeijer, JT, Kalkman, DN, et al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care, 2017 published online Dec 6. DOI:10.2337/dc17-1722.
22. Buckley, LF, Dixon, DL, Wohlford, GF 4th, Wijesinghe, DS, Baker, WL, Van Tassell, BW, Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care 40 (2017), 1733–1738.
23. Whelton, PK, Carey, RM, Aronow, WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary—a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2017 published online Nov 13. DOI:10.1016/j.jacc.2017.11.005.
24. de Boer, IH, Bangalore, S, Benetos, A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care, 40, 2017, 1273.
25. Cherney, DZ, Scholey, JW, Miller, JA, Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4 (2008), 280–290.
26. Barratt, A, Wyer, PC, Hatala, R, et al. Tips for learners of evidence-based medicine: 1—relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 171 (2004), 353–358.